Johnson & Johnson stock: EUR 240.80, down 2.01% premarket
Published on 11/06/2026 at 07:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSFDA Approval Expands Oncology Reach
- Johnson & Johnson received accelerated U.S. approval for RYBREVANT FASPRO in recurrent or metastatic head and neck cancer.
- The decision extends the drug's use beyond non-small cell lung cancer and supports the company's oncology growth strategy.
- Continued approval depends on confirmation of clinical benefit in an ongoing Phase 3 trial.
Johnson & Johnson said the U.S. Food and Drug Administration granted accelerated approval on Thursday, November 5, for RYBREVANT FASPRO as a single-agent treatment for adults with recurrent or metastatic head and neck squamous cell carcinoma whose disease progressed after platinum-based chemotherapy and an anti-PD-(L)1 antibody. The indication excludes HPV-associated oropharyngeal cancer. The company's press release said the approval is based on the Phase 1b/2 OrigAMI-4 study, which reported a 42 percent overall response rate.
Johnson & Johnson stock traded at 240.80 euros on Lang & Schwarz at 07:55 CET on Friday, November 6, 2026, 2.01 percent below the Xetra close of Thursday, November 5. Investors can follow the real-time quote of Johnson & Johnson stock.
The regulatory decision gives Johnson & Johnson a new commercial application for amivantamab beyond non-small cell lung cancer. The company said the therapy targets EGFR and MET pathways and is delivered by subcutaneous injection. The approval is accelerated, so continued authorization may depend on confirmation of clinical benefit in the ongoing Phase 3 OrigAMI-5 study.
For the broader U.S. market backdrop, investors can follow the S&P 500.
